Romina Mizrahi

ORCID: 0000-0001-6667-7928
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Schizophrenia research and treatment
  • Tryptophan and brain disorders
  • Functional Brain Connectivity Studies
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Cannabis and Cannabinoid Research
  • Neuroscience and Neuropharmacology Research
  • Neurotransmitter Receptor Influence on Behavior
  • Stress Responses and Cortisol
  • Mental Health and Psychiatry
  • Medical Imaging Techniques and Applications
  • Alzheimer's disease research and treatments
  • Dementia and Cognitive Impairment Research
  • Advanced Neuroimaging Techniques and Applications
  • Radiopharmaceutical Chemistry and Applications
  • Psychosomatic Disorders and Their Treatments
  • Bipolar Disorder and Treatment
  • Mental Health Research Topics
  • Treatment of Major Depression
  • Receptor Mechanisms and Signaling
  • Neurological disorders and treatments
  • S100 Proteins and Annexins
  • Alcohol Consumption and Health Effects
  • Advanced MRI Techniques and Applications
  • Neurobiology of Language and Bilingualism
  • Lanthanide and Transition Metal Complexes

McGill University
2020-2025

Douglas Mental Health University Institute
2021-2025

Centre for Addiction and Mental Health
2015-2024

Douglas College
2021-2024

Art Research Centre of the Slovak Academy of Sciences
2024

Seoul National University
2024

University of Toronto
2012-2022

Mental Health Research Institute
2015-2022

Campo Arqueologico de Mertola
2017-2020

Canada Research Chairs
2013-2020

The neuroinflammatory hypothesis of major depressive disorder is supported by several main findings. First, in humans and animals, activation the immune system causes sickness behaviors that present during a episode (MDE), such as low mood, anhedonia, anorexia, weight loss. Second, peripheral markers inflammation are frequently reported disorder. Third, illnesses associated with high rates MDEs. However, fundamental limitation paucity evidence brain MDE. Translocator protein density measured...

10.1001/jamapsychiatry.2014.2427 article EN JAMA Psychiatry 2015-01-28

OBJECTIVE: This study examined the frequency of major and minor depression in Alzheimer’s disease determined whether these types have a different functional psychopathological impact there is change prevalence throughout stages disease. METHOD: A consecutive series 670 patients with probable were assessed Structured Clinical Interview for DSM-IV; specific instruments to rate presence severity depression, anxiety, apathy, irritability, delusions, pathological affective crying, performance...

10.1176/appi.ajp.162.11.2086 article EN American Journal of Psychiatry 2005-11-01

Objective: Aripiprazole has a unique pharmacological profile that includes partial agonism at D 2 receptors, antagonism 5-HT and 1A receptors. The authors conducted positron emission tomography (PET) study to characterize the simultaneous effects of aripiprazole , receptors in patients with schizophrenia or schizoaffective disorder. Method: Twelve who had previously received antipsychotic treatment were randomly assigned receive 10 mg, 15 20 30 mg aripiprazole. After least 14 days treatment,...

10.1176/appi.ajp.2007.06091479 article EN American Journal of Psychiatry 2007-08-29

For a small percentage of obsessive-compulsive disorder (OCD) cases exhibiting additional neuropsychiatric symptoms, it was proposed that neuroinflammation occurs in the basal ganglia as an autoimmune response to infections. However, is possible elevated neuroinflammation, inducible by diverse range mechanisms, important throughout cortico-striato-thalamo-cortical circuit OCD. Identifying brain inflammation with recent advance positron emission tomography (PET) radioligands bind translocator...

10.1001/jamapsychiatry.2017.1567 article EN JAMA Psychiatry 2017-06-21

Neuroinflammation and abnormal immune responses have been implicated in schizophrenia (SCZ). Past studies using positron emission tomography (PET) that examined neuroinflammation patients with SCZ vivo the translocator protein 18kDa (TSPO) target were limited by insensitivity of first-generation imaging agent [(11)C]-PK11195, scanners used, small sample sizes studied. Present study uses a novel second-generation TSPO PET radioligand...

10.1093/schbul/sbu157 article EN Schizophrenia Bulletin 2014-11-09

[ 18 F]-FEPPA binds to the 18-kDa translocator protein (TSPO) and is used in positron emission tomography (PET) detect microglial activation. However, quantitative interpretations of PET signal with new generation TSPO radioligands are confounded by large interindividual variability binding affinity. This presents as a trimodal distribution, reflecting high-affinity binders (HABs), low-affinity binder (LAB), mixed-affinity (MABs). Here, we show that one polymorphism (rs6971) located exon 4...

10.1038/jcbfm.2012.46 article EN Journal of Cerebral Blood Flow & Metabolism 2012-04-04

Objective: Neuroinflammation and abnormal immune responses are increasingly implicated in the pathophysiology of schizophrenia. Previous positron emission tomography (PET) studies targeting translocator protein 18 kDa (TSPO) have been limited by high nonspecific binding first-generation radioligand, low-resolution scanners, small sample sizes, psychotic patients being on antipsychotics or not first episode their illness. The present study uses novel second-generation TSPO PET radioligand...

10.1176/appi.ajp.2016.16020171 article EN American Journal of Psychiatry 2016-09-09

This study investigated whether the second-generation translocator protein 18kDa (TSPO) radioligand, [18F]-FEPPA, could be used in neurodegenerative parkinsonian disorders as a biomarker for detecting neuroinflammation striatum. Neuroinflammation has been implicated potential mechanism progression of Parkinson's disease (PD). Positron Emission Tomography (PET) radioligand targeting TSPO allows quantification vivo. Based on genotype rs6791 polymorphism gene, 16 mixed-affinity binders (MABs)...

10.1371/journal.pone.0138721 article EN cc-by PLoS ONE 2015-09-18

Monoamine oxidase B (MAO-B) is an important, high-density enzyme in the brain that generates oxidative stress by hydrogen peroxide production, alters mitochondrial function, and metabolizes nonserotonergic monoamines. Recent advances positron emission tomography radioligand development for MAO-B humans enable highly quantitative measurement of distribution volume (MAO-B VT), index density. To date, this first investigation major depressive disorder evaluates regions beyond raphe amygdala.To...

10.1001/jamapsychiatry.2019.0044 article EN JAMA Psychiatry 2019-03-06

Abstract Machine learning approaches using structural magnetic resonance imaging (sMRI) can be informative for disease classification, although their ability to predict psychosis is largely unknown. We created a model with individuals at CHR who developed later (CHR-PS+) from healthy controls (HCs) that differentiate each other. also evaluated whether we could distinguish CHR-PS+ those did not develop (CHR-PS-) and uncertain follow-up status (CHR-UNK). T1-weighted brain MRI scans 1165...

10.1038/s41380-024-02426-7 article EN cc-by Molecular Psychiatry 2024-02-09

Abstract [ 11 C]‐(+)‐PHNO (4‐propyl‐9‐hydroxynaphthoxazine) is a new agonist radioligand that provides unique opportunity to measure the high‐affinity states of D 2 receptors (D ‐high) using positron emission tomography (PET). Here we report on distribution, displaceablity, specificity and modeling compare it with well characterized antagonist radioligand, C]raclopride, in cat. displayed high uptake striatum mean striatal binding potential (BP) 3.95 ± 0.85. Pre‐treatment specific 1...

10.1111/j.1471-4159.2006.03840.x article EN Journal of Neurochemistry 2006-04-05

To determine the frequency, and demographic clinical correlates of dangerous behaviours in Alzheimer's disease (AD). We assessed a consecutive series 278 patients with AD 45 age‐comparable healthy controls comprehensive psychiatric neuropsychological evaluation. Caregivers rated frequency patients’ exposure to situations or commission behaviours. The was 16% group 2% control group. presence anosognosia associated threefold increase risk behaviours, but there no significant association...

10.1111/j.1468-1331.2007.01745.x article EN European Journal of Neurology 2007-03-23
Coming Soon ...